GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » TOWA Pharmaceutical Co Ltd (FRA:6QC) » Definitions » Beneish M-Score

TOWA Pharmaceutical Co (FRA:6QC) Beneish M-Score : -2.15 (As of Jun. 04, 2024)


View and export this data going back to 2021. Start your Free Trial

What is TOWA Pharmaceutical Co Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.15 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for TOWA Pharmaceutical Co's Beneish M-Score or its related term are showing as below:

FRA:6QC' s Beneish M-Score Range Over the Past 10 Years
Min: -2.73   Med: -2.36   Max: -1.47
Current: -2.15

During the past 13 years, the highest Beneish M-Score of TOWA Pharmaceutical Co was -1.47. The lowest was -2.73. And the median was -2.36.


TOWA Pharmaceutical Co Beneish M-Score Historical Data

The historical data trend for TOWA Pharmaceutical Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TOWA Pharmaceutical Co Beneish M-Score Chart

TOWA Pharmaceutical Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.47 -2.34 -2.03 -2.37 -2.15

TOWA Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.37 - - - -2.15

Competitive Comparison of TOWA Pharmaceutical Co's Beneish M-Score

For the Drug Manufacturers - Specialty & Generic subindustry, TOWA Pharmaceutical Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TOWA Pharmaceutical Co's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, TOWA Pharmaceutical Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where TOWA Pharmaceutical Co's Beneish M-Score falls into.



TOWA Pharmaceutical Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of TOWA Pharmaceutical Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.232+0.528 * 0.9751+0.404 * 0.8333+0.892 * 0.9591+0.115 * 1.2712
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1+4.679 * 0.018486-0.327 * 1.0145
=-2.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Total Receivables was €386 Mil.
Revenue was €1,400 Mil.
Gross Profit was €500 Mil.
Total Current Assets was €1,337 Mil.
Total Assets was €2,645 Mil.
Property, Plant and Equipment(Net PPE) was €943 Mil.
Depreciation, Depletion and Amortization(DDA) was €110 Mil.
Selling, General, & Admin. Expense(SGA) was €0 Mil.
Total Current Liabilities was €492 Mil.
Long-Term Debt & Capital Lease Obligation was €1,161 Mil.
Net Income was €99 Mil.
Gross Profit was €0 Mil.
Cash Flow from Operations was €50 Mil.
Total Receivables was €327 Mil.
Revenue was €1,459 Mil.
Gross Profit was €508 Mil.
Total Current Assets was €1,279 Mil.
Total Assets was €2,595 Mil.
Property, Plant and Equipment(Net PPE) was €887 Mil.
Depreciation, Depletion and Amortization(DDA) was €136 Mil.
Selling, General, & Admin. Expense(SGA) was €0 Mil.
Total Current Liabilities was €549 Mil.
Long-Term Debt & Capital Lease Obligation was €1,050 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(386.352 / 1399.688) / (326.987 / 1459.435)
=0.276027 / 0.22405
=1.232

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(508.093 / 1459.435) / (499.753 / 1399.688)
=0.348144 / 0.357046
=0.9751

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (1336.954 + 943.479) / 2644.537) / (1 - (1278.671 + 887.46) / 2594.845)
=0.137682 / 0.165218
=0.8333

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=1399.688 / 1459.435
=0.9591

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(135.623 / (135.623 + 887.46)) / (109.846 / (109.846 + 943.479))
=0.132563 / 0.104285
=1.2712

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(0 / 1399.688) / (0 / 1459.435)
=0 / 0
=1

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((1161.365 + 491.985) / 2644.537) / ((1050.342 + 548.734) / 2594.845)
=0.625195 / 0.616251
=1.0145

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(99.315 - 0 - 50.428) / 2644.537
=0.018486

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

TOWA Pharmaceutical Co has a M-score of -2.27 suggests that the company is unlikely to be a manipulator.


TOWA Pharmaceutical Co Beneish M-Score Related Terms

Thank you for viewing the detailed overview of TOWA Pharmaceutical Co's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


TOWA Pharmaceutical Co (FRA:6QC) Business Description

Traded in Other Exchanges
Address
2-11, Shinbashi-cho, Kadoma, Osaka, JPN, 571-8580
TOWA Pharmaceutical Co Ltd is a Japan based pharmaceutical company engaged in research and development, production, and marketing of generic drugs. It also provides drug consulting services for patients and their families and relatives. It organizes academic seminars for medical professionals and posts articles in journals. It participates in training for pharmacists. The company has three main plants in operation namely Osaka plant, Okayama plant, and Yamagata plant. Towa has offers more than 500 drugs to meet the diverse therapeutic requirements including lifestyle related diseases such as hypertension and diabetes, digestive system diseases, nervous system diseases and allergic diseases, vitamins and antibiotics.

TOWA Pharmaceutical Co (FRA:6QC) Headlines

No Headlines